CYP1A1 and 1B1‐mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical Pharmacology"
DOI: 10.1016/j.bcp.2018.10.012
Abstract: &NA; Dolutegravir (DTG), a potent integrase inhibitor, is part of a recommended initial regimen for the treatment of human immunodeficiency virus (HIV). Prior reports demonstrated that the clearance of DTG was higher in current smokers… read more here.
Keywords: cyp1a1 1b1; metabolic pathways; dtg; mediated metabolic ... See more keywords